Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection
Viral infections complicated by a bacterial infection are typically referred to as coinfections or superinfections. Streptococcus pyogenes, the group A streptococcus (GAS), is not the most common bacteria associated with influenza A virus (IAV) superinfections but did cause significant mortality dur...
Gespeichert in:
| Veröffentlicht in: | PloS one 2020-06, Vol.15 (6), p.e0235139 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | e0235139 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Herrera, Andrea L Van Hove, Christopher Hanson, Mary Dale, James B Tweten, Rodney K Huber, Victor C Diel, Diego Chaussee, Michael S |
| description | Viral infections complicated by a bacterial infection are typically referred to as coinfections or superinfections. Streptococcus pyogenes, the group A streptococcus (GAS), is not the most common bacteria associated with influenza A virus (IAV) superinfections but did cause significant mortality during the 2009 influenza pandemic even though all isolates are susceptible to penicillin. One approach to improve the outcome of these infections is to use passive immunization targeting GAS. To test this idea, we assessed the efficacy of passive immunotherapy using antisera against either the streptococcal M protein or streptolysin O (SLO) in a murine model of IAV-GAS superinfection. Prophylactic treatment of mice with antiserum to either SLO or the M protein decreased morbidity compared to mice treated with non-immune sera; however, neither significantly decreased mortality. Therapeutic use of antisera to SLO decreased morbidity compared to mice treated with non-immune sera but neither antisera significantly reduced mortality. Overall, the results suggest that further development of antibodies targeting the M protein or SLO may be a useful adjunct in the treatment of invasive GAS diseases, including IAV-GAS superinfections, which may be particularly important during influenza pandemics. |
| doi_str_mv | 10.1371/journal.pone.0235139 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2416238495</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A627453481</galeid><doaj_id>oai_doaj_org_article_2c418d96b3b144f8aca7dc263a00005a</doaj_id><sourcerecordid>A627453481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6739-a49bd5c260b3e072c3d21d8f583456d8b2a0a946f2c77e34a9a84656751e20083</originalsourceid><addsrcrecordid>eNqNkl2L1DAUhoso7rr6D0QDguDFjPlueyMMix8DKwOuehtO07TToW26Sbo4gv_djNNdpqBgc9H05DlvD2_eJHlO8JKwlLzd2dH10C4H25slpkwQlj9IzknO6EJSzB6e7M-SJ97vMBYsk_JxcsaoSDnF4jz5te66sbdhaxwMexTA1SY0fY1iBV0HZ4ZgtdV69GjY29r0xqPPaHA2mKZH1iF_ZNq9j98bFCyKBQiHo8GZW9MH1PRVO5r-J6AV8uNgXCwYHRrbP00eVdB682x6XyTfPrz_evlpcbX5uL5cXS20TFm-AJ4XpdBU4oIZnFLNSkrKrBIZ40KWWUEBQ85lRXWaGsYhh4xLIVNBDMU4YxfJy6Pu0FqvJue8opxIyjKei0isj0RpYacG13Tg9spCo_4UrKsVuNDo1iiqOcnKXBasIJxXGWhIyzgcAxwfAVHr3fS3sehMqaMHDtqZ6Pykb7aqtrcqZQTHe4kCryYBZ29G48M_Rp6oGuJU0VMbxXTXeK1WkqZcMJ6RSC3_QsVVmq7RMTtVE-uzhjezhsgE8yPUMHqv1tdf_p_dfJ-zr0_YrYE2bL1tx0MO_BzkR1A7670z1b1zBKtD9O_cUIfoqyn6se3Fqev3TXdZZ78BazUAPw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2416238495</pqid></control><display><type>article</type><title>Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Herrera, Andrea L ; Van Hove, Christopher ; Hanson, Mary ; Dale, James B ; Tweten, Rodney K ; Huber, Victor C ; Diel, Diego ; Chaussee, Michael S</creator><creatorcontrib>Herrera, Andrea L ; Van Hove, Christopher ; Hanson, Mary ; Dale, James B ; Tweten, Rodney K ; Huber, Victor C ; Diel, Diego ; Chaussee, Michael S</creatorcontrib><description>Viral infections complicated by a bacterial infection are typically referred to as coinfections or superinfections. Streptococcus pyogenes, the group A streptococcus (GAS), is not the most common bacteria associated with influenza A virus (IAV) superinfections but did cause significant mortality during the 2009 influenza pandemic even though all isolates are susceptible to penicillin. One approach to improve the outcome of these infections is to use passive immunization targeting GAS. To test this idea, we assessed the efficacy of passive immunotherapy using antisera against either the streptococcal M protein or streptolysin O (SLO) in a murine model of IAV-GAS superinfection. Prophylactic treatment of mice with antiserum to either SLO or the M protein decreased morbidity compared to mice treated with non-immune sera; however, neither significantly decreased mortality. Therapeutic use of antisera to SLO decreased morbidity compared to mice treated with non-immune sera but neither antisera significantly reduced mortality. Overall, the results suggest that further development of antibodies targeting the M protein or SLO may be a useful adjunct in the treatment of invasive GAS diseases, including IAV-GAS superinfections, which may be particularly important during influenza pandemics.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0235139</identifier><identifier>PMID: 32574205</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Animal models ; Animals ; Antibodies ; Antibodies, Bacterial - blood ; Antibodies, Bacterial - immunology ; Antigens, Bacterial - immunology ; Antigens, Bacterial - metabolism ; Antisera ; Bacterial diseases ; Bacterial infections ; Bacterial Outer Membrane Proteins - antagonists & inhibitors ; Bacterial Outer Membrane Proteins - immunology ; Bacterial Outer Membrane Proteins - metabolism ; Bacterial Proteins - antagonists & inhibitors ; Bacterial Proteins - immunology ; Bacterial Proteins - metabolism ; Biology and Life Sciences ; Care and treatment ; Carrier Proteins - antagonists & inhibitors ; Carrier Proteins - immunology ; Carrier Proteins - metabolism ; Coinfection - microbiology ; Coinfection - therapy ; Coinfection - virology ; Control ; Female ; Host-Pathogen Interactions - drug effects ; Host-Pathogen Interactions - immunology ; Humans ; Immune Sera - immunology ; Immune Sera - pharmacology ; Immune serum ; Immunization ; Immunization (passive) ; Immunotherapy ; Immunotherapy - methods ; Infections ; Influenza ; Influenza A ; Influenza A virus - immunology ; Influenza A virus - physiology ; Medical treatment ; Medicine and Health Sciences ; Methods ; Mice, Inbred BALB C ; Morbidity ; Mortality ; Orthomyxoviridae Infections - immunology ; Orthomyxoviridae Infections - therapy ; Orthomyxoviridae Infections - virology ; Pandemics ; Penicillin ; Prevention ; Proteins ; Rabbits ; Research and Analysis Methods ; Streptococcal Infections - immunology ; Streptococcal Infections - microbiology ; Streptococcal Infections - therapy ; Streptococcal M protein ; Streptococcus infections ; Streptococcus pyogenes ; Streptococcus pyogenes - immunology ; Streptococcus pyogenes - metabolism ; Streptococcus pyogenes - physiology ; Streptolysins - antagonists & inhibitors ; Streptolysins - immunology ; Streptolysins - metabolism ; Superinfection ; Superinfection - microbiology ; Superinfection - therapy ; Superinfection - virology ; Viruses</subject><ispartof>PloS one, 2020-06, Vol.15 (6), p.e0235139</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Herrera et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Herrera et al 2020 Herrera et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6739-a49bd5c260b3e072c3d21d8f583456d8b2a0a946f2c77e34a9a84656751e20083</citedby><cites>FETCH-LOGICAL-c6739-a49bd5c260b3e072c3d21d8f583456d8b2a0a946f2c77e34a9a84656751e20083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310742/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310742/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32574205$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Herrera, Andrea L</creatorcontrib><creatorcontrib>Van Hove, Christopher</creatorcontrib><creatorcontrib>Hanson, Mary</creatorcontrib><creatorcontrib>Dale, James B</creatorcontrib><creatorcontrib>Tweten, Rodney K</creatorcontrib><creatorcontrib>Huber, Victor C</creatorcontrib><creatorcontrib>Diel, Diego</creatorcontrib><creatorcontrib>Chaussee, Michael S</creatorcontrib><title>Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Viral infections complicated by a bacterial infection are typically referred to as coinfections or superinfections. Streptococcus pyogenes, the group A streptococcus (GAS), is not the most common bacteria associated with influenza A virus (IAV) superinfections but did cause significant mortality during the 2009 influenza pandemic even though all isolates are susceptible to penicillin. One approach to improve the outcome of these infections is to use passive immunization targeting GAS. To test this idea, we assessed the efficacy of passive immunotherapy using antisera against either the streptococcal M protein or streptolysin O (SLO) in a murine model of IAV-GAS superinfection. Prophylactic treatment of mice with antiserum to either SLO or the M protein decreased morbidity compared to mice treated with non-immune sera; however, neither significantly decreased mortality. Therapeutic use of antisera to SLO decreased morbidity compared to mice treated with non-immune sera but neither antisera significantly reduced mortality. Overall, the results suggest that further development of antibodies targeting the M protein or SLO may be a useful adjunct in the treatment of invasive GAS diseases, including IAV-GAS superinfections, which may be particularly important during influenza pandemics.</description><subject>Animal models</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Bacterial - blood</subject><subject>Antibodies, Bacterial - immunology</subject><subject>Antigens, Bacterial - immunology</subject><subject>Antigens, Bacterial - metabolism</subject><subject>Antisera</subject><subject>Bacterial diseases</subject><subject>Bacterial infections</subject><subject>Bacterial Outer Membrane Proteins - antagonists & inhibitors</subject><subject>Bacterial Outer Membrane Proteins - immunology</subject><subject>Bacterial Outer Membrane Proteins - metabolism</subject><subject>Bacterial Proteins - antagonists & inhibitors</subject><subject>Bacterial Proteins - immunology</subject><subject>Bacterial Proteins - metabolism</subject><subject>Biology and Life Sciences</subject><subject>Care and treatment</subject><subject>Carrier Proteins - antagonists & inhibitors</subject><subject>Carrier Proteins - immunology</subject><subject>Carrier Proteins - metabolism</subject><subject>Coinfection - microbiology</subject><subject>Coinfection - therapy</subject><subject>Coinfection - virology</subject><subject>Control</subject><subject>Female</subject><subject>Host-Pathogen Interactions - drug effects</subject><subject>Host-Pathogen Interactions - immunology</subject><subject>Humans</subject><subject>Immune Sera - immunology</subject><subject>Immune Sera - pharmacology</subject><subject>Immune serum</subject><subject>Immunization</subject><subject>Immunization (passive)</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Infections</subject><subject>Influenza</subject><subject>Influenza A</subject><subject>Influenza A virus - immunology</subject><subject>Influenza A virus - physiology</subject><subject>Medical treatment</subject><subject>Medicine and Health Sciences</subject><subject>Methods</subject><subject>Mice, Inbred BALB C</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Orthomyxoviridae Infections - immunology</subject><subject>Orthomyxoviridae Infections - therapy</subject><subject>Orthomyxoviridae Infections - virology</subject><subject>Pandemics</subject><subject>Penicillin</subject><subject>Prevention</subject><subject>Proteins</subject><subject>Rabbits</subject><subject>Research and Analysis Methods</subject><subject>Streptococcal Infections - immunology</subject><subject>Streptococcal Infections - microbiology</subject><subject>Streptococcal Infections - therapy</subject><subject>Streptococcal M protein</subject><subject>Streptococcus infections</subject><subject>Streptococcus pyogenes</subject><subject>Streptococcus pyogenes - immunology</subject><subject>Streptococcus pyogenes - metabolism</subject><subject>Streptococcus pyogenes - physiology</subject><subject>Streptolysins - antagonists & inhibitors</subject><subject>Streptolysins - immunology</subject><subject>Streptolysins - metabolism</subject><subject>Superinfection</subject><subject>Superinfection - microbiology</subject><subject>Superinfection - therapy</subject><subject>Superinfection - virology</subject><subject>Viruses</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl2L1DAUhoso7rr6D0QDguDFjPlueyMMix8DKwOuehtO07TToW26Sbo4gv_djNNdpqBgc9H05DlvD2_eJHlO8JKwlLzd2dH10C4H25slpkwQlj9IzknO6EJSzB6e7M-SJ97vMBYsk_JxcsaoSDnF4jz5te66sbdhaxwMexTA1SY0fY1iBV0HZ4ZgtdV69GjY29r0xqPPaHA2mKZH1iF_ZNq9j98bFCyKBQiHo8GZW9MH1PRVO5r-J6AV8uNgXCwYHRrbP00eVdB682x6XyTfPrz_evlpcbX5uL5cXS20TFm-AJ4XpdBU4oIZnFLNSkrKrBIZ40KWWUEBQ85lRXWaGsYhh4xLIVNBDMU4YxfJy6Pu0FqvJue8opxIyjKei0isj0RpYacG13Tg9spCo_4UrKsVuNDo1iiqOcnKXBasIJxXGWhIyzgcAxwfAVHr3fS3sehMqaMHDtqZ6Pykb7aqtrcqZQTHe4kCryYBZ29G48M_Rp6oGuJU0VMbxXTXeK1WkqZcMJ6RSC3_QsVVmq7RMTtVE-uzhjezhsgE8yPUMHqv1tdf_p_dfJ-zr0_YrYE2bL1tx0MO_BzkR1A7670z1b1zBKtD9O_cUIfoqyn6se3Fqev3TXdZZ78BazUAPw</recordid><startdate>20200623</startdate><enddate>20200623</enddate><creator>Herrera, Andrea L</creator><creator>Van Hove, Christopher</creator><creator>Hanson, Mary</creator><creator>Dale, James B</creator><creator>Tweten, Rodney K</creator><creator>Huber, Victor C</creator><creator>Diel, Diego</creator><creator>Chaussee, Michael S</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200623</creationdate><title>Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection</title><author>Herrera, Andrea L ; Van Hove, Christopher ; Hanson, Mary ; Dale, James B ; Tweten, Rodney K ; Huber, Victor C ; Diel, Diego ; Chaussee, Michael S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6739-a49bd5c260b3e072c3d21d8f583456d8b2a0a946f2c77e34a9a84656751e20083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animal models</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Bacterial - blood</topic><topic>Antibodies, Bacterial - immunology</topic><topic>Antigens, Bacterial - immunology</topic><topic>Antigens, Bacterial - metabolism</topic><topic>Antisera</topic><topic>Bacterial diseases</topic><topic>Bacterial infections</topic><topic>Bacterial Outer Membrane Proteins - antagonists & inhibitors</topic><topic>Bacterial Outer Membrane Proteins - immunology</topic><topic>Bacterial Outer Membrane Proteins - metabolism</topic><topic>Bacterial Proteins - antagonists & inhibitors</topic><topic>Bacterial Proteins - immunology</topic><topic>Bacterial Proteins - metabolism</topic><topic>Biology and Life Sciences</topic><topic>Care and treatment</topic><topic>Carrier Proteins - antagonists & inhibitors</topic><topic>Carrier Proteins - immunology</topic><topic>Carrier Proteins - metabolism</topic><topic>Coinfection - microbiology</topic><topic>Coinfection - therapy</topic><topic>Coinfection - virology</topic><topic>Control</topic><topic>Female</topic><topic>Host-Pathogen Interactions - drug effects</topic><topic>Host-Pathogen Interactions - immunology</topic><topic>Humans</topic><topic>Immune Sera - immunology</topic><topic>Immune Sera - pharmacology</topic><topic>Immune serum</topic><topic>Immunization</topic><topic>Immunization (passive)</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Infections</topic><topic>Influenza</topic><topic>Influenza A</topic><topic>Influenza A virus - immunology</topic><topic>Influenza A virus - physiology</topic><topic>Medical treatment</topic><topic>Medicine and Health Sciences</topic><topic>Methods</topic><topic>Mice, Inbred BALB C</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Orthomyxoviridae Infections - immunology</topic><topic>Orthomyxoviridae Infections - therapy</topic><topic>Orthomyxoviridae Infections - virology</topic><topic>Pandemics</topic><topic>Penicillin</topic><topic>Prevention</topic><topic>Proteins</topic><topic>Rabbits</topic><topic>Research and Analysis Methods</topic><topic>Streptococcal Infections - immunology</topic><topic>Streptococcal Infections - microbiology</topic><topic>Streptococcal Infections - therapy</topic><topic>Streptococcal M protein</topic><topic>Streptococcus infections</topic><topic>Streptococcus pyogenes</topic><topic>Streptococcus pyogenes - immunology</topic><topic>Streptococcus pyogenes - metabolism</topic><topic>Streptococcus pyogenes - physiology</topic><topic>Streptolysins - antagonists & inhibitors</topic><topic>Streptolysins - immunology</topic><topic>Streptolysins - metabolism</topic><topic>Superinfection</topic><topic>Superinfection - microbiology</topic><topic>Superinfection - therapy</topic><topic>Superinfection - virology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Herrera, Andrea L</creatorcontrib><creatorcontrib>Van Hove, Christopher</creatorcontrib><creatorcontrib>Hanson, Mary</creatorcontrib><creatorcontrib>Dale, James B</creatorcontrib><creatorcontrib>Tweten, Rodney K</creatorcontrib><creatorcontrib>Huber, Victor C</creatorcontrib><creatorcontrib>Diel, Diego</creatorcontrib><creatorcontrib>Chaussee, Michael S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Herrera, Andrea L</au><au>Van Hove, Christopher</au><au>Hanson, Mary</au><au>Dale, James B</au><au>Tweten, Rodney K</au><au>Huber, Victor C</au><au>Diel, Diego</au><au>Chaussee, Michael S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2020-06-23</date><risdate>2020</risdate><volume>15</volume><issue>6</issue><spage>e0235139</spage><pages>e0235139-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Viral infections complicated by a bacterial infection are typically referred to as coinfections or superinfections. Streptococcus pyogenes, the group A streptococcus (GAS), is not the most common bacteria associated with influenza A virus (IAV) superinfections but did cause significant mortality during the 2009 influenza pandemic even though all isolates are susceptible to penicillin. One approach to improve the outcome of these infections is to use passive immunization targeting GAS. To test this idea, we assessed the efficacy of passive immunotherapy using antisera against either the streptococcal M protein or streptolysin O (SLO) in a murine model of IAV-GAS superinfection. Prophylactic treatment of mice with antiserum to either SLO or the M protein decreased morbidity compared to mice treated with non-immune sera; however, neither significantly decreased mortality. Therapeutic use of antisera to SLO decreased morbidity compared to mice treated with non-immune sera but neither antisera significantly reduced mortality. Overall, the results suggest that further development of antibodies targeting the M protein or SLO may be a useful adjunct in the treatment of invasive GAS diseases, including IAV-GAS superinfections, which may be particularly important during influenza pandemics.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>32574205</pmid><doi>10.1371/journal.pone.0235139</doi><tpages>e0235139</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-06, Vol.15 (6), p.e0235139 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2416238495 |
| source | Public Library of Science (PLoS) Journals Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Animal models Animals Antibodies Antibodies, Bacterial - blood Antibodies, Bacterial - immunology Antigens, Bacterial - immunology Antigens, Bacterial - metabolism Antisera Bacterial diseases Bacterial infections Bacterial Outer Membrane Proteins - antagonists & inhibitors Bacterial Outer Membrane Proteins - immunology Bacterial Outer Membrane Proteins - metabolism Bacterial Proteins - antagonists & inhibitors Bacterial Proteins - immunology Bacterial Proteins - metabolism Biology and Life Sciences Care and treatment Carrier Proteins - antagonists & inhibitors Carrier Proteins - immunology Carrier Proteins - metabolism Coinfection - microbiology Coinfection - therapy Coinfection - virology Control Female Host-Pathogen Interactions - drug effects Host-Pathogen Interactions - immunology Humans Immune Sera - immunology Immune Sera - pharmacology Immune serum Immunization Immunization (passive) Immunotherapy Immunotherapy - methods Infections Influenza Influenza A Influenza A virus - immunology Influenza A virus - physiology Medical treatment Medicine and Health Sciences Methods Mice, Inbred BALB C Morbidity Mortality Orthomyxoviridae Infections - immunology Orthomyxoviridae Infections - therapy Orthomyxoviridae Infections - virology Pandemics Penicillin Prevention Proteins Rabbits Research and Analysis Methods Streptococcal Infections - immunology Streptococcal Infections - microbiology Streptococcal Infections - therapy Streptococcal M protein Streptococcus infections Streptococcus pyogenes Streptococcus pyogenes - immunology Streptococcus pyogenes - metabolism Streptococcus pyogenes - physiology Streptolysins - antagonists & inhibitors Streptolysins - immunology Streptolysins - metabolism Superinfection Superinfection - microbiology Superinfection - therapy Superinfection - virology Viruses |
| title | Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T15%3A37%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunotherapy%20targeting%20the%20Streptococcus%20pyogenes%20M%20protein%20or%20streptolysin%20O%20to%20treat%20or%20prevent%20influenza%20A%20superinfection&rft.jtitle=PloS%20one&rft.au=Herrera,%20Andrea%20L&rft.date=2020-06-23&rft.volume=15&rft.issue=6&rft.spage=e0235139&rft.pages=e0235139-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0235139&rft_dat=%3Cgale_plos_%3EA627453481%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2416238495&rft_id=info:pmid/32574205&rft_galeid=A627453481&rft_doaj_id=oai_doaj_org_article_2c418d96b3b144f8aca7dc263a00005a&rfr_iscdi=true |